MoonLake gets FDA, EMA feedback on Phase 3 study (NASDAQ:MLTX)

Andrzej Rostek

MoonLake Immunotherapeutics (NASDAQ:MLTX) said it has received feedback from the FDA and European Medicines Agency on its proposed Phase 3 study for its drug sonelokimab in the treatment of hidradenitis suppurativa, or HS.

The biotech company said it received guidance on

Source link

Related Articles

Back to top button